Whitehawk Therapeutics Inc
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $271.4M
- Price
- $4.76
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.59%
- Volume
- 151.6K
About
Whitehawk Therapeutics Inc operates as a clinical-stage biopharmaceutical company. The Company develops precision therapies for genetically-defined cancers.
Quick stats
Shares outstanding57.0M
Computed float14.5M
Float / shares25.4%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001422142
Websitehttps://ir.whitehawktx.com
AI Summary
AI-generated1/17
minorbullishearnings
Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
Whitehawk Therapeutics reported a Q2 net loss of $16.6 million, or $0.20 per share, with no revenue for the period. R&D expenses decreased to $12.9 million compared to the prior year's quarter which included a one-time license fee.
The company bolstered its balance sheet with $190.0 million in cash and investments following an $87.5 million private placement in May. Management projects this capital will fund operations into the second half of 2028.
Operationally, Whitehawk is enrolling patients in Phase 1 trials for HWK-007 and HWK-016 and remains on track to initiate the HWK-206 trial in Q3 2026. Recent strategic moves include option agreements with Hangzhou DAC and a collaboration with Biocytogen to expand its ADC platform.